Reality investigation of minimal residual disease in acute leukemia or how laboratory acrobatics is really necessary?
Abstract
The methods presented in the article are certainly proof of the technical possibilities of contemporary molecular cytogenetics and molecular genetics. The idea that should be used routinely , or even paid with public funds, but rather playful and even the authors themselves it can not be serious.
Financial and time aspects and needs of instrumentation including chemicals ( mFISH / mBAND , Library 25,000 probes , special machine for DNA combing , mikrodisektor , a new generation sequencer , etc.) , predispose this method as opposed to technical curiosities. Additionally , resulting from one of three examined samples for finding a fusion gene MLL/AF4 which is commonly observed at the level of the transcript.
Genomic break for reliable MRD monitoring at the level of DNA in the majority of mergers involving the MLL gene found by inverse PCR. If we wanted to accept the idea that (at least for a proportion of patients with AML) need to seek individual , yet undescribed targets for MRD monitoring is already currently cheaper and faster option directly transkriptomová , exomová or even whole genome sequencing sample.